OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
Lupu’s findings were published in the Proceedings of the National Academy of Sciences.
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.
New research will help physicians better identify blood relatives of lupus patients at risk for developing the disease.
Since 1946, OMRF has grown into an internationally recognized research institute.